메뉴 건너뛰기




Volumn 273, Issue 5272, 1996, Pages 252-255

Platelet-mediated lymphocyte delivery to high endothelial venules

Author keywords

[No Author keywords available]

Indexed keywords

SELECTIN;

EID: 0029794005     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5272.252     Document Type: Article
Times cited : (280)

References (45)
  • 1
    • 0027982876 scopus 로고
    • T. A. Springer, Cell 76, 301 (1994); E. C. Butcher and L. J. Picker, Science 272, 60 (1996).
    • (1994) Cell , vol.76 , pp. 301
    • Springer, T.A.1
  • 2
  • 10
    • 0028178252 scopus 로고
    • S. A. Michie, P. R. Streeter, P. A. Bolt, E. C. Butcher, L. J. Picker, Am. J. Pathol. 143, 1688 (1993); J. P. Turunen et al., Eur. J. Immunol. 24, 1130 (1994).
    • (1994) Eur. J. Immunol. , vol.24 , pp. 1130
    • Turunen, J.P.1
  • 12
    • 0003919972 scopus 로고    scopus 로고
    • in press
    • Mice were anesthetized by intraperitoneal injection (0.2 ml) of a mixture of ketamine (5 mg/ml) and xylazine (1 mg/ml), and catheters were inserted into the right jugular vein (for injection of anesthesia and mAb), the left carotid artery (for blood pressure monitoring), and the right femoral artery (for retrograde injection of fluorescently labeled cells). Subsequently, the left subiliac LN was microsurgically prepared for intravital microscopy as described (U. H. von Andrian, Microcirculation, in press). The preparation was transferred to a custom-built intravital microscope (IV-500; Micron Instruments, San Diego, CA). For microscopic observation of endogenous microvascular WBC behavior, a bolus injection of sterile Ringer's lactate (10 ml per kilogram of body weight) containing the fluorescent dye rhodamine 6G (2 mg/ ml; Molecular Probes) was given intravenously. Rhodamine 6G stains nuclei and mitochondria in living cells, thereby permitting visualization of interacting and freely flowing leukocytes in LN HEVs by fluorescent stroboscopic epi-illumination through a 20× Zeiss objective. Video scenes were recorded through a low-lag SIT camera (Dage MTI) and stored on Hi 8 videotape for off-line analysis of rolling fractions, rolling velocities, and microvascular hemodynamics as described [U. H. von Andrian et al., Am. J. Physiol. 263, H1034 (1992)]. After a 3- to 5-min control recording of HEVs, some animals were treated with mAb Mel-14 [100 μg per mouse, intravenously (iv)], and leukocyte behavior in the same vascular bed was recorded 15 min later.
    • Microcirculation
    • Von Andrian, U.H.1
  • 13
    • 0026445853 scopus 로고
    • Mice were anesthetized by intraperitoneal injection (0.2 ml) of a mixture of ketamine (5 mg/ml) and xylazine (1 mg/ml), and catheters were inserted into the right jugular vein (for injection of anesthesia and mAb), the left carotid artery (for blood pressure monitoring), and the right femoral artery (for retrograde injection of fluorescently labeled cells). Subsequently, the left subiliac LN was microsurgically prepared for intravital microscopy as described (U. H. von Andrian, Microcirculation, in press). The preparation was transferred to a custom-built intravital microscope (IV-500; Micron Instruments, San Diego, CA). For microscopic observation of endogenous microvascular WBC behavior, a bolus injection of sterile Ringer's lactate (10 ml per kilogram of body weight) containing the fluorescent dye rhodamine 6G (2 mg/ ml; Molecular Probes) was given intravenously. Rhodamine 6G stains nuclei and mitochondria in living cells, thereby permitting visualization of interacting and freely flowing leukocytes in LN HEVs by fluorescent stroboscopic epi-illumination through a 20× Zeiss objective. Video scenes were recorded through a low-lag SIT camera (Dage MTI) and stored on Hi 8 videotape for off-line analysis of rolling fractions, rolling velocities, and microvascular hemodynamics as described [U. H. von Andrian et al., Am. J. Physiol. 263, H1034 (1992)]. After a 3- to 5-min control recording of HEVs, some animals were treated with mAb Mel-14 [100 μg per mouse, intravenously (iv)], and leukocyte behavior in the same vascular bed was recorded 15 min later.
    • (1992) Am. J. Physiol. , vol.263
    • Von Andrian, U.H.1
  • 15
    • 0027940593 scopus 로고
    • Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 μm for 5 min) in the presence of 2 mM Arg-Gl-Asp-Ser (RGDS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 U/ml, 5 min, 37°C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 μg/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2′,7′-bis-(2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the node. In some experiments (n = 3), mAb MECA-79 (100 μg per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.
    • (1994) J. Immunol. , vol.153 , pp. 3917
    • Jutila, M.A.1
  • 16
    • 0028809484 scopus 로고
    • Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 μm for 5 min) in the presence of 2 mM Arg-Gl-Asp-Ser (RGDS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 U/ml, 5 min, 37°C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 μg/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2′,7′-bis-(2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the node. In some experiments (n = 3), mAb MECA-79 (100 μg per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.
    • (1995) J. Exp. Med. , vol.182 , pp. 1337
    • Liau, F.1
  • 17
    • 0027982055 scopus 로고
    • Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 μm for 5 min) in the presence of 2 mM Arg-Gl-Asp-Ser (RGDS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 U/ml, 5 min, 37°C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 μg/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2′,7′-bis-(2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the node. In some experiments (n = 3), mAb MECA-79 (100 μg per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.
    • (1994) J. Clin. Invest. , vol.94 , pp. 1243
    • Diacovo, T.G.1    De Fougerolles, A.R.2    Bainton, D.F.3    Springer, T.A.4
  • 21
    • 0026758565 scopus 로고
    • K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
    • (1992) Biochem. Blophys. Res. Commun. , vol.186 , pp. 173
    • Moore, K.L.1    Thompson, L.F.2
  • 22
    • 0027272394 scopus 로고
    • K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
    • (1993) Blood , vol.82 , pp. 1165
    • Buttrum, S.M.1    Hatton, R.2    Nash, G.B.3
  • 23
    • 0026495238 scopus 로고
    • K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
    • (1992) Nature , vol.359 , pp. 848
    • Palabrica, T.1
  • 24
    • 0029947679 scopus 로고    scopus 로고
    • K. L. Moore and L. F. Thompson, Biochem. Blophys. Res. Commun. 186, 173 (1992); S. M. Buttrum, R. Hatton, G. B. Nash, Blood 82, 1165 (1993); T. Palabrica et al., Nature 359, 848 (1992); T. G. Diacovo, S. J. Roth, J. Buccola, D. F. Bainton, T. A. Springer, Blood 88, 146 (1996).
    • (1996) Blood , vol.88 , pp. 146
    • Diacovo, T.G.1    Roth, S.J.2    Buccola, J.3    Bainton, D.F.4    Springer, T.A.5
  • 26
    • 0027138212 scopus 로고
    • D. Sako et al., Cell 75, 1179 (1993).
    • (1993) Cell , vol.75 , pp. 1179
    • Sako, D.1
  • 28
    • 9444283433 scopus 로고    scopus 로고
    • note
    • 7 per milliliter), and injected into mice as described (12).
  • 30
    • 0027496220 scopus 로고
    • S. Baumhueter et al., Science 262, 436 (1993); L. A. Lasky et al., Cell 69, 927 (1992).
    • (1993) Science , vol.262 , pp. 436
    • Baumhueter, S.1
  • 31
    • 0026776328 scopus 로고
    • S. Baumhueter et al., Science 262, 436 (1993); L. A. Lasky et al., Cell 69, 927 (1992).
    • (1992) Cell , vol.69 , pp. 927
    • Lasky, L.A.1
  • 34
    • 0026763332 scopus 로고
    • C. Foxall et al., J. Cell Biol. 117, 895 (1992); R. E. Mebius and S. R. Watson, J. Immunol. 151, 3252 (1993).
    • (1992) J. Cell Biol. , vol.117 , pp. 895
    • Foxall, C.1
  • 35
    • 0027185994 scopus 로고
    • C. Foxall et al., J. Cell Biol. 117, 895 (1992); R. E. Mebius and S. R. Watson, J. Immunol. 151, 3252 (1993).
    • (1993) J. Immunol. , vol.151 , pp. 3252
    • Mebius, R.E.1    Watson, S.R.2
  • 36
    • 0027212673 scopus 로고
    • U. H. von Andrian et al., Blood 82, 182 (1993); K. E. Norgard-Sumnicht, N. M. Varki, A. Varki, Science 261, 480 (1993); K. Ley, T. F. Tedder, G. S. Kansas, Blood 82, 1632 (1993).
    • (1993) Blood , vol.82 , pp. 182
    • Von Andrian, U.H.1
  • 37
    • 0027248439 scopus 로고
    • U. H. von Andrian et al., Blood 82, 182 (1993); K. E. Norgard-Sumnicht, N. M. Varki, A. Varki, Science 261, 480 (1993); K. Ley, T. F. Tedder, G. S. Kansas, Blood 82, 1632 (1993).
    • (1993) Science , vol.261 , pp. 480
    • Norgard-Sumnicht, K.E.1    Varki, N.M.2    Varki, A.3
  • 38
    • 0027178702 scopus 로고
    • U. H. von Andrian et al., Blood 82, 182 (1993); K. E. Norgard-Sumnicht, N. M. Varki, A. Varki, Science 261, 480 (1993); K. Ley, T. F. Tedder, G. S. Kansas, Blood 82, 1632 (1993).
    • (1993) Blood , vol.82 , pp. 1632
    • Ley, K.1    Tedder, T.F.2    Kansas, G.S.3
  • 39
    • 0028147864 scopus 로고
    • H.-A. Lehr et al., Lab. Invest. 71, 380 (1994); H.-A. Lehr, B. Frei, K.-E. Arfors, Proc. Natl. Acad. Sci. U.S.A. 91, 7688 (1994).
    • (1994) Lab. Invest. , vol.71 , pp. 380
    • Lehr, H.-A.1
  • 43
    • 0026014586 scopus 로고
    • A. R. Pries, Int. J. Microcirc. Clin. Exp. 7, 327 (1988); K. Ley and P. Gaehtgens, Circ. Res. 69, 1034 (1991).
    • (1991) Circ. Res. , vol.69 , pp. 1034
    • Ley, K.1    Gaehtgens, P.2
  • 45
    • 9444279784 scopus 로고    scopus 로고
    • note
    • We thank B. Fors, E. Finger, and G. Cheng for technical assistance; E. Butcher, P. Newman, D. Wagner, G. Gaudernack, and R. McEver for contributing reagents; and K. Gauvreau for aiding in statistical analysis. Supported by National Institutes of Health grants HL48675 and HL54936.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.